NCT03946800View on ClinicalTrials.gov

A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

May 8, 2019

Primary Completion Date

August 24, 2023

Study Completion Date

August 24, 2023

Conditions
Solid TumorsCancer
Interventions
BIOLOGICAL

MEDI1191

Subjects will receive MEDI1191 (at least twice)

BIOLOGICAL

Durvalumab

Subject will receive durvalumab every 4 weeks

Trial Locations (11)

10029

Research Site, New York

10065

Research Site, New York

10461

Research Site, The Bronx

28027

Research Site, Madrid

31008

Research Site, Pamplona

77030

Research Site, Houston

90025

Research Site, Los Angeles

90089

Research Site, Los Angeles

92093

Research Site, La Jolla

02903

Research Site, Providence

08035

Research Site, Barcelona

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY